SLC5A1 and chronic kidney disease: GIP secretion was stimulated by glucose and the non-metabolisable SGLT1 substrate α-MDG, and glucose-triggered GIP release was inhibited by sotagliflozin, an SGLT1/2 blocker used for management of diabetes and chronic kidney disease [23].